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Observational studies in which researchers have
investigated the effect of sex on the outcome of infrain-
guinal arterial reconstruction have provided conflicting
results.1-4 Because these studies have primarily includ-
ed procedures with autogenous vein grafts, less is
known about the outcome of women undergoing pro-
cedures with prosthetic grafts. Most reports, which
were conducted with stratified analyses, have demon-
strated differences in graft patency between subsets of
men and women.2,3 Specific risk factors related to
women, such as the effect of hormone replacement
therapy (HRT), have not been considered as previous
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studies have compared the results of treatment 
in both genders evaluating the same risk factors. 
None of these reports have focused on women with
femoropopliteal bypass graft procedures.
Evidence from numerous observational studies
demonstrates that HRT reduces the primary risk of
cardiovascular disease in previously healthy post-
menopausal women.5-8 However, the potential 
benefit of HRT as secondary prevention has been
questioned. A recent randomized clinical trial docu-
mented that hormone therapy increases the risk of
coronary and thromboembolic events in women
with established cardiovascular disease.9 The effect
of HRT on women with established peripheral vas-
cular disease has not been defined.
Difficulties have been encountered when infrain-
guinal bypass grafts with different levels of distal
anastomosis are compared. The angiographic runoff
score of the Ad Hoc scoring system (Society for
Vascular Surgery/North American Chapter of the
International Society for Cardiovascular Surgery
[SVS/ISCVS]) has proved to be useful in predicting
the outcome of infrainguinal arterial reconstruction
procedures.10-12 Because bypass grafts to the
popliteal artery are not comparable to bypass grafts
to more distal levels, unless equal numbers of proce-
dures are present in both groups, one should include
and compare only those procedures with equivalent
runoff scores.
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We investigated the outcome of women under-
going femoropopliteal bypass graft surgery and
defined preoperative factors, surgical procedures,
and complications that are predictive of adverse
results. The effect of estrogen replacement therapy
on graft patency, in particular, was analyzed, and the
association with an increased risk for thromboem-
bolic events in women with preexisting cardiovascu-
lar disease was recognized.
METHODS
During a 5-year period (June 1993 to June
1998), 131 consecutive femoropopliteal bypass graft
procedures were performed in 106 women at the
University of Tennessee Medical Center at Knoxville,
and all patients were included in a cohort study. All
patients were postmenopausal and had evidence of
chronic limb ischemia. Demographic data, risk fac-
tors, complications, and outcome variables were
defined according to the criteria prepared and revised
by the Ad Hoc Committee on Reporting Standards
(SVS/ISCVS).10 Preoperative evaluation of all
patients included the taking of a history and the per-
formance of a physical examination, an electrocardio-
gram, a chest radiograph, blood work, noninvasive
vascular determination of ankle-brachial and toe-
brachial indices, arteriogram of the aorta and runoff
vessels, and cardiac testing as indicated. The bypass
grafting procedures were performed with the patients
Fig 1. Primary graft patency after femoropopliteal bypass grafting was significantly lower in HRT users
compared with nonusers (Kaplan-Meier method, log-rank test, P = .004). HRT, Hormone replace-
ment therapy.
under general or regional anesthesia and with stan-
dard vascular surgical techniques. Variables analyzed
included age, indication for operation and extent of
ischemia, comorbidities (diabetes mellitus, hyperten-
sion, coronary artery disease, cerebrovascular disease,
end-stage renal disease, smoking history, previous
revascularization procedures), use of HRT, runoff
score, type of graft conduit, level of distal anastomo-
sis, and use of aspirin or warfarin. Runoff was classi-
fied from the review of both preoperative and intra-
operative arteriograms (Ad Hoc Committee on
Reporting Standards, SVS/ISCVS).10 The angio-
graphic runoff score was further used for subgroup
analysis; runoff scores were categorized as poor
(score ≥ 5) and good (score < 5).
HRT was defined as the long-term use of stan-
dard-dose estrogen, equivalent to 0.625 mg of con-
jugated equine estrogen daily, or the long-term use
of standard-dose estrogen plus a progestin. Neither
patients taking oral contraceptives nor patients using
selective estrogen receptor modulators such as
tamoxifen were included in the study. HRT use was
assessed by questioning the patients at each follow-
up visit. However, hormone levels were not mea-
sured.
Preoperative, intraoperative, and follow-up
information was available in all patients and was
obtained by means of office and hospital chart
review, dictated operative records, and telephone
conversations with patients, physicians, or family
members. There was no strict postoperative surveil-
lance protocol. However, the patients were usually
seen within 2 weeks from the time of surgery.
Improvement and changes in clinical status were
determined by history and noninvasive vascular lab-
oratory tests. At the discretion of the attending sur-
geon, postoperative follow-up (clinical and graft sur-
veillance duplex scan) was conducted every 3
months during the first postoperative year and every
6 months thereafter. If a graft stenosis was found,
more frequent studies were conducted until reoper-
ative surgery was performed. Arteriography was per-
formed in most cases of early stenosis or when
duplex scanning revealed a decrease in an ankle-
brachial index of 0.15 or more, a drop in graft peak
systolic velocity to less than 40 cm/s, or an increase
to more than 300 cm/s with a velocity ratio greater
than 3.5. All revisions performed that were based on
these criteria were considered graft failures and the
end of primary patency.13 Survival could be estab-
lished by telephone contact, but graft patency and
limb salvage were determined at the date of the most
recent examination.
On the basis of prior reports and for sample size
calculations, the enrollment of patients undergoing
a minimum of 128 procedures (32 in the HRT
group and 96 in the non-HRT group) with a two-
sided type I error rate of 0.05 would be necessary to
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Table I. Patients’ characteristics of HRT users and nonusers
Users of HRT (%) Nonusers of HRT (%)
(n = 34) (n = 97) P value
Mean age (y) 59.8 69.7 < .001*
Comorbidities
Diabetes mellitus 12 (36) 49 (51) NS
Hypertension 34 (100) 71 (73) .001†
Tobacco abuse 31 (91) 61 (63) .003†
Coronary artery disease 23 (68) 68 (70) NS
Renal insufficiency (Cr > 1.6) 9 (27) 24 (25) NS
Previous vascular reconstruction 5 (15) 12 (12) NS
Indications
Claudication 9 (27) 17 (18) NS
Rest pain 13 (38) 36 (37) NS
Tissue loss 12 (35) 44 (44) NS
Distal anastomosis
Above-knee popliteal 21 (62) 47 (49) NS
Below-knee popliteal 13 (38) 50 (52) NS
Poor runoff (score > 5) 16 (47) 57 (59) NS
Graft conduit
In situ saphenous 7 (21) 31 (32) NS
Excised vein 5 (15) 21 (22) NS
PTFE 22 (64) 45 (46) NS
*Student t test for nonpaired samples.
†χ2 Analysis.
Cr, Creatinine level; NS, not significant.
obtain at least 90% power to detect a decrease in the
5-year primary graft patency rate, from 70% in non-
HRT users to 35% in HRT users (relative risk [RR],
2).14-20 Our sample size was defined during the
study design and was large enough to fulfill such an
estimation.
Demographic data and risk factors were com-
pared between HRT users and nonusers. Continuous
variables were analyzed with the Student t test, and
univariate analysis of categoric variables was per-
formed with the Fisher exact test or χ2 test with Yates
correction, as indicated (χ2 for contingency tables, 2-
tailed P value). All analyses were performed accord-
ing to the intention-to-treat principle. Primary,
assisted primary, and secondary graft patency; limb
salvage; and patient survival were determined with
the Kaplan-Meier method.21 The log-rank test
(Mantel-Haenszel test) was used to specify statistical
differences for each variable between the subgroups.
To avoid double counting of cumulative survival
events in patients who underwent multiple index
procedures, we only included follow-up times of sur-
vival for the first procedure. The Cox proportional
hazards model was used for multivariate analysis to
assess the influence of various risk factors on graft
patency, limb salvage, and patient survival. Variables
that had a P value less than .10 in the univariate
analysis and those known to be important or possible
confounding factors were entered into the regression
model and considered significant by forward stepwise
selection if the P value was less than .05 in the final
regression equation. By this method, the RR and
95% CIs for the different variables were also estimat-
ed, which validated the statistical differences from a
clinical and epidemiologic standpoint.22,23 For statis-
tical analyses, SPSS for Windows version 9.0 (SPSS
Inc, Chicago, Ill) was used.24
RESULTS
The average age of the 106 patients was 66.4
years (range, 32-88 years). The mean follow-up peri-
od was 34.4 months, with a range from 3 to 77
months. The most commonly associated risk factors
in the overall group were hypertension (80%), sig-
nificant history of tobacco use (70%), coronary
artery disease (69%), hyperlipidemia (69%), and dia-
betes mellitus (47%). Other risk factors included a
history of cerebrovascular disease (32%), chronic
obstructive pulmonary disease (32%), and end-stage
renal disease (4%). Indications for revascularization
were limb salvage in 104 procedures (80%; ischemic
rest pain in 49 [35%]; tissue loss in 55 [45%]) and
disabling claudication in 26 (20%). Autogenous vein
was used in 63 procedures (48%), polytetrafluo-
roethylene (PTFE) in 64 (49%), and PTFE-vein
composite grafts in 4 (3%). Sixty-eight bypass graft-
ing procedures were femoral to above-knee popliteal
(52%), and 63 bypass grafting procedures were
femoral to below-knee popliteal (48%). Most
femoral to above-knee popliteal bypass graft recon-
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Fig 2. Primary graft patency after above-knee femoropopliteal bypass grafting with prosthetic grafts
was significantly lower in HRT users compared with nonusers (Kaplan-Meier method, log-rank test, P
= .022). AK, Above-knee; HRT, hormone replacement therapy; PTFE, polytetrafluoroethylene.
structions were performed with PTFE (46 of 68
[68%]), whereas autogenous vein was mainly used
for femoral to below-knee popliteal procedures (42
of 63 [67%]). Of the autogenous vein grafts, 38
were in situ saphenous vein grafts (29%), 24 were
reverse saphenous vein grafts (18%), and one proce-
dure was performed with arm vein (0.8%). The
inflow artery was the common femoral artery in 112
patients (85%), proximal superficial femoral artery in
17 patients (13%), and distal superficial femoral
artery in 2 patients (2%). Previous ipsilateral lower
limb revascularization had been performed in 18
patients (14%).
Fourteen patients (11%) had undergone previous
inflow procedures, and 18 patients (14%) had con-
comitant inflow procedures. The 32 inflow proce-
dures consisted of 12 aortobifemoral, 3 iliofemoral,
and 5 axillobifemoral bypass grafts; 4 common
femoral endarterectomies; and 10 iliac transluminal
angioplasties. Twenty-one women (16%) required
revascularization of the contralateral extremity dur-
ing follow-up, with a mean interval between proce-
dures of 8 months (range, 1-35 months). Wound
infections developed in 14 patients (10%), but only
four patients (3%) had deep infections that required
drainage. No graft infections occurred.
Thirty-four patients (26%) were receiving HRT
preoperatively. None of the patients either discon-
tinued or started HRT during the follow-up period.
Twenty-five patients (19%) were receiving only
estrogen therapy, whereas nine patients (7%) were
receiving combined therapy with estrogen and pro-
gestin. Women receiving HRT were significantly
older than those not receiving replacement therapy
(P < .001). Furthermore, HRT users had a signifi-
cantly higher frequency of hypertension (100% vs
73%; P = .001) and a history of tobacco use (91% vs
63%; P = .003), with no other significant differences
noted by univariate analysis (Table I). Nonusers of
HRT had a higher frequency of diabetes, but this
difference was not significant (50% vs 35%; P = .12).
The frequency and distribution of indications for
revascularization, level of distal anastomosis, types of
bypass graft conduit, and runoff scores were not sig-
nificantly different between HRT users and
nonusers.
Primary graft patency rates for all women at 1, 3,
and 5 years were 81%, 65%, and 56%, respectively.
Primary graft patency rates for HRT users at 1, 3, and
5 years were 75%, 45%, and 23%, respectively. Primary
graft patency rates for HRT nonusers at 1, 3, and 5
years were 84%, 72%, and 65%, respectively. Users of
HRT had a significant, decreased primary graft paten-
cy with respect to nonusers by means of univariate
analysis (Fig 1; Kaplan-Meier method, log-rank test, P
= .004). Women with renal disease (creatinine level ≥
1.6 mg/dL) also had statistically significant decreased
primary patency rates (Kaplan-Meier method, log-rank
test, P = .043). Primary graft patency rates for women
with renal disease at 1, 3, and 5 years were 73%, 47%,
and 35%, and for women without renal disease they
were 85%, 73%, and 61%, respectively. Primary graft
patency rates were not significantly different for the
other variables analyzed. Primary graft patency rates
for smokers at 1, 3, and 5 years were 78%, 65%, and
50%, respectively. Primary graft patency rates for non-
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Table II. Independent predictors of graft patency, limb salvage, and cumulative survival*
Coefficient RR† 95% CI P value
Primary patency
HRT 0.914 2.5 1.3-4.8 .006
HRT with estrogen only 0.916 2.5 1.3-5.0 .009
HRT + PTFE 1.191 3.3 1.4-7.5 .005
Assisted primary patency
HRT 1.044 2.8 1.4-5.6 .003
Renal insufficiency (Cr > 1.6) 0.784 2.2 1.1-4.3 .025
Secondary patency
Prosthetic graft (PTFE) 0.951 2.6 1.1-6.1 .03
Renal insufficiency (Cr > 1.6) 0.796 2.2 1.1-4.8 .04
HRT + PTFE 0.923 2.5 1.1-6.2 .04
Limb salvage
Previous vascular reconstruction 2.267 9.6 1.7-54 .01
Cumulative survival
Diabetes 1.386 3.9 1.2-12.5 .017
*Variables with a P value less than .1 with the univariate analysis were entered into the multivariate Cox regression models and selected
by forward stepwise selection if P value was less than .05 (P < .001 for models).
†RR of adverse outcome (ie, decreased patency, limb salvage, and survival) for each predictor.
Cr, Creatinine level.
smokers at 1, 3, and 5 years were 89%, 73%, and 68%,
respectively. There was no significant difference in pri-
mary patency rates between smokers and nonsmokers
(Kaplan-Meier method, log-rank test, P = .171).
Primary graft patency rates for patients with diabetes
and those without diabetes were also compared, and
there was no significant difference (Kaplan-Meier
method, log-rank test, P = .807). There was a trend to
decreased primary patency rates among patients with a
poor runoff (score ≥ 5); however, this trend did not
achieve statistical significance. In addition, primary
patency rates were not significantly different as to the
level of distal anastomosis (above- vs below-knee
popliteal), types of graft conduit used (autogenous
vein vs PTFE), and history of previous revasculariza-
tion. Cox regression analysis revealed that HRT use
was the only independent predictor of decreased pri-
mary graft patency when controlling for the presence
of all other risk factors (RR, 2.5; 95% CI, 1.3-4.8; P =
.006). Women receiving HRT who underwent a
bypass graft procedure with PTFE, in particular, had
the lowest primary patency (RR, 3.4; 95% CI, 1.5-7.8;
P = .003). The exclusion of users of combined estro-
gen and progestin therapy from the analyses did not
change the results; the risk of reduced primary graft
patency was also significantly increased in women tak-
ing only estrogen (Table II).
Users of HRT undergoing above-knee bypass
grafts with PTFE had a significant, decreased primary
graft patency with respect to nonusers by means of
stratified analysis (Kaplan-Meier method, log-rank
test, P = .023); the primary patency rates at 1, 3, and
5 years were 67%, 45%, and 22% for HRT users and
90%, 70%, and 62%, respectively, for nonusers (Fig 2).
Stratified univariate and multivariate analyses
including only the first femoropopliteal bypass graft
procedure in each patient (ie, considering the
patient as the unit of study) revealed similar results;
users of HRT had a significant, decreased primary
graft patency with respect to nonusers by means of
univariate analysis (Kaplan-Meier method, log-rank
test, P = .027). Primary graft patency rates at 1, 3,
and 5 years were 78%, 53%, and 35% for HRT users
and 85%, 72%, and 70%, respectively, for HRT
nonusers. The use of HRT was also identified as the
only independent predictor of decreased primary
graft patency (RR, 2.3; 95% CI, 1.1-4.9; P = .013).
These additional calculations were done with a num-
ber of patients (106), enough to obtain a power of
at least 80% and an α error of .05.
For all women, assisted primary patency rates at
1, 3, and 5 years were 96%, 92%, and 92%, respec-
tively. Univariate and multivariate regression analy-
ses identified HRT use and history of renal disease as
the independent risk factors for decreased assisted
primary patency (Table II; Fig 3).
Early graft thrombosis (within 30 days) occurred
after six procedures (4.6%; all autogenous vein).
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Fig 3. Assisted primary graft patency after femoropopliteal bypass grafting was significantly lower in
HRT users than in nonusers (Kaplan-Meier method log-rank test, P = .001). HRT, Hormone replace-
ment therapy.
Late graft thrombosis occurred after 32 procedures
(24%; eight autogenous vein, 24 PTFE). Among the
38 patients who had graft thrombosis, 26 (68%) had
normal duplex surveillance scans, and 12 (32%) had
focal flow abnormalities (peak systolic velocity > 150
cm/s, velocity ratio > 1.5) with moderate graft
stenosis confirmed at operation. Univariate analysis
revealed a significantly higher frequency of graft
thrombosis among HRT users (41% vs 21%; P =
.027); the RR was 1.9-fold higher than that of
nonusers (χ2 test; 95% CI, 1.1-3.3). In 15 patients
(12%), 18 sites of high-grade graft stenosis (peak sys-
tolic velocity > 300 and velocity ratio > 3.4) were
detected with duplex scan surveillance and were sub-
sequently repaired. Users and nonusers of HRT had
a similar frequency of graft stenosis (14% vs 10%; P
= .49). The secondary graft patency rates for the
entire series of patients were 89%, 73%, and 66% at
1, 3, and 5 years, respectively, after surgery.
Secondary patency rates for HRT users at 1, 3, and
5 years were 90%, 59%, and 44%, and for nonusers
they were 89%, 76%, and 71%, respectively. There
was no statistically significant difference between
these groups (Kaplan-Meier method, log-rank test,
P = .095). A history of renal disease and the use of
PTFE graft were independent predictors of
decreased secondary patency by means of multivari-
ate analysis (Table II). In the subgroup of women
who underwent a procedure with prosthetic materi-
al, HRT use was an independent predictor of
reduced secondary patency (RR, 2.6; 95% CI, 1.1-
6.6; P = .035; Fig 3).
For all women, limb salvage at 1, 3, and 5 years
was 96%, 92%, and 92%, respectively. Limb salvage
analyses with the Kaplan-Meier method and log-rank
test revealed no significant differences with HRT use.
Although not statistically significant, there was a
trend toward decreased limb salvage among women
with diabetes (P = .07), renal disease (P = .06), and
poor runoff (P = .13) and among women receiving
HRT (P = .09), as compared with their counterparts
(Kaplan-Meier method, log-rank test). A history of
previous ipsilateral vascular procedure was the only
independent predictor of reduced limb salvage by
means of multivariate analysis (Table II; Fig 4).
No operative (30-day) deaths occurred. Overall,
long-term survival was 96% at 1 year, 86% at 3 years,
and 74% at 5 years. Long-term survival in women
receiving HRT was 95% at 1 year, 90% at 3 years,
and 78% at 5 years. Long-term survival in women
not receiving HRT was 96% at 1 year, 85% at 3 years,
and 72% at 5 years. There was no significant differ-
ence in survival between HRT users and nonusers
(Fig 1; Kaplan-Meier method, log-rank test, P =
.72). Diabetes mellitus was the only independent
predictor of decreased long-term survival by means
of multivariate analysis (risk ratio, 5.6; 95% CI, 1.6-
18.4; P = .006; Table II; Fig 5).
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Fig 4. Secondary graft patency after femoropopliteal bypass grafting with prosthetic grafts was signif-
icantly lower in HRT users compared with nonusers (Kaplan-Meier method, log-rank test, P = .031).
HRT, Hormone replacement therapy; PTFE, polytetrafluoroethylene.
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DISCUSSION
This study indicates that HRT use is a main fac-
tor contributing to decreased primary graft patency
after femoropopliteal bypass graft procedures in
women. In previous studies, investigators have ana-
lyzed sex as a predictor of adverse outcome without
analyzing specific risk factors for women, such as the
use of HRT.1-4 Furthermore, these studies have not
always included women undergoing procedures with
prosthetic grafts. Despite conflicting results, stratified
analysis and the evaluation of subgroups of patients
have revealed evident differences between the
sexes.2,3,25,26 For instance, women undergoing revas-
cularization procedures for limb salvage and bypass
graft procedures to the tibial arteries have reduced
primary patency rates. Smaller vessel size has been
suggested as a possible cause of these differences, but
this assumption has also been questioned in the liter-
ature because of inconsistent results.27 The etiology
for infrainguinal bypass graft failure in women has
not been identified in previous studies.
Prospective and retrospective observational stud-
ies have demonstrated that HRT reduces the primary
risk of coronary artery disease in healthy post-
menopausal women.5-8 Less is known about the influ-
ence of HRT in women with cardiovascular disease.
The Heart and Estrogen/Progestin Replacement
Study, the first randomized clinical trial in which the
effect of estrogens plus medroxyprogesterone in post-
menopausal women with established cardiovascular
disease was analyzed, revealed that HRT was associat-
ed with an increased rate of thromboembolic and
coronary events. These authors recommend not start-
ing HRT as a secondary prevention of coronary heart
disease.9 The exact mechanism of increased risk for
coronary events is unknown. The effects of estrogens,
progestin, or both on nonvascular tissues, such as the
liver, may cause a prothrombotic and proischemic
state with an altered coagulation profile.28-30 These
effects may outweigh the proposed favorable influ-
ence of estrogens on lipoproteins, atherosclerosis, and
endothelial function.7,31-33 Additional evidence of the
effect of postmenopausal hormones on the risk of
thrombosis has been reported. Investigators of three
large epidemiologic studies independently found that
current users of HRT had a twofold to threefold
increase in the risk for both deep venous thrombosis
and pulmonary embolism.34-36 The risk was highest
in the first few years of use, and the risk was increased
for both estrogen alone and estrogen plus progestin.
Some studies report rises in clotting factor concentra-
tions, whereas others indicate no in vitro coagulabili-
ty changes among HRT users.7,29,30
In our series, multivariate analyses identified
HRT use, including either estrogen plus progestin
or estrogen alone, as the only predictor of decreased
primary and assisted primary graft patency. An
increased risk of thromboembolic events in patients
receiving HRT may account for this adverse out-
come. The fact that patients undergoing reconstruc-
tion with PTFE and receiving HRT had the lowest
primary patency rates may indicate an adverse asso-
ciation of two thrombogenic factors. Although HRT
Fig 5. Limb salvage after femoropopliteal bypass grafting was significantly lower in women with pre-
vious vascular reconstruction (Kaplan-Meier method, log-rank test, P = .03).
users had significantly higher frequency of graft
thrombosis without an underlying previous graft
lesion, this feature is not specific of patients using
HRT, particularly because half of the procedures
were performed with prosthetic grafts. As previous-
ly reported, graft lesions are uncommon in all
patients with prosthetic bypass grafts in whom graft
thrombosis subsequently developed.37
This study does adhere to the current criteria
prepared and revised by the Ad Hoc Committee on
Reporting Standards (SVS/ISCVS).10 However,
basing the different analyses on the number of
femoral popliteal bypass grafts, rather than individ-
ual patients, may be recognized as a limitation
because of a possible overestimation of the influence
of risk factors particular to those patients who had
undergone more than one femoropopliteal bypass
graft procedure. Therefore, stratified analyses were
obtained including only the first procedure per-
formed in each patient. These additional calculations
(considering the patient and not the graft as the unit
of study) revealed similar results; HRT was the only
independent predictor of decreased primary graft
patency.
Given the significantly reduced primary graft
patency for reconstructions with PTFE in HRT
users, even for above-knee femoropopliteal bypass
grafts, our results favor the use of venous recon-
structions in HRT users. For HRT nonusers, how-
ever, prosthetic materials for above-knee bypass
grafts were an acceptable option.
Women using HRT were older and had a higher
frequency of hypertension and history of tobacco
use. These risk factors, however, failed to explain the
adverse outcome of HRT users because they were
neither statistically significant by means of univariate
analysis nor independent predictors by means of
multivariate analysis of decreased primary and assist-
ed primary graft patency.
Renal insufficiency and the use of a prosthetic
graft were independent risk factors for decreased sec-
ondary graft patency; HRT use was also identified as
an independent risk factor for those women under-
going procedures with prosthetic grafts. As reported
in previous studies, diabetes was the only indepen-
dent predictor of decreased survival.1,38,39
Although HRT users had a reduced primary
graft patency, additional interventions provided
effective limb salvage. On the basis of our findings,
HRT users who undergo femoropopliteal bypass
graft procedures should be considered for diligent
postoperative graft surveillance with early interven-
tion even for thrombosed grafts. Anticoagulation
therapy, particularly, should be investigated as a fac-
tor to improve the patency rate for these patients at
high risk for graft failure.
The lack of randomization and potential bias in
patient selection are limitations of any observational
study. In our study, different variables, including the
patterns of use of HRT, and the various outcomes
were evaluated in a clinical setting. Our data indicate
a decrease in primary graft patency associated with
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Fig 6. Cumulative patient survival after femoropopliteal bypass grafting was significantly lower in
patients with diabetes than in those without (Kaplan-Meier method, log-rank test, P = .011).
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HRT use after femoropopliteal bypass graft proce-
dures. These observations suggest the need for fur-
ther studies to investigate the significance of HRT
for reconstructions at other vascular sites and to dis-
sect mechanisms of HRT-mediated graft failure.
CONCLUSIONS
Women undergoing femoropopliteal bypass graft
reconstructions who are receiving HRT have a signif-
icantly reduced primary graft patency. The risk of graft
failure increases when prosthetic materials are used.
Among HRT users, autogenous venous recon-
struction for femoropopliteal occlusive disease offers
better results when this conduit is available.
Reconstruction with PTFE may be considered as an
acceptable option for nonusers of HRT.
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The appendices featuring the Kaplan-Meier
method curves are available on the web.
DISCUSSION
Dr Joseph L. Mills (Tucson, Ariz). First of all, welcome
to Tucson. Secondly, it was certainly an honor to be asked
to discuss a paper about sex. When I told my wife this, she
was sort of astounded and said, “Why would they ask you
to talk about a topic about which you know so little?” I
actually had to go to the library to look up some data on
estrogens.
The effect of gender on graft patency after infrain-
guinal bypass is controversial. Previous reports analyzing
primarily autogenous vein grafts generally show no differ-
ences in outcome between men and women, although
some have suggested that women do slightly worse. The
authors sought to reexamine this issue as well as determine
whether or not hormone replacement therapy, or HRT,
influences outcome after leg bypass surgery. This issue is
of some importance. As you all know, women live longer
than men. It has been estimated that by the year 2040,
20% of the population will be over 65 years of age, and
two thirds of them will be women. 
Now, estrogen has beneficial effects on the fibrinolyt-
ic system and lowers lipid levels. Three different meta-
analyses concluded that ERT, or estrogen replacement
therapy, decreased the risk of coronary heart disease by
35% to 50%. This “protective” effect of estrogen was felt
to be well founded. However, in the 1998 JAMA study to
which the authors alluded, the so-called HERS study, a
randomized trial of estrogen plus progestin for secondary
prevention of coronary disease in postmenopausal women
was published, and a total of 2763 postmenopausal
women with documented coronary disease were random-
ized to placebo or ERT. There were no significant differ-
ences in coronary or peripheral vascular events between
the hormone group and the placebo group despite an 11%
reduction in LDL levels in the hormone group.
The authors of the present study evaluated 132 fem-
pop bypasses performed on 106 women over a 5-year peri-
od. There are several curious features of this series I would
like the authors to address. First, 80% of the patients
underwent bypass for limb salvage; however, the vein uti-
lization rate was extremely low. Only 49% of patients had
vein grafts. This is most unusual for a limb salvage setting.
In addition, the distal anastomosis was above the knee in
53% of patients, which again is surprisingly high for a limb
salvage series. In our most recent 155 distal bypasses, only
four were performed with PTFE, and only 7% had above-
knee popliteal anastomoses. Does this pattern in the
authors’ series reflect a difference in patient characteristics
or a preference to bypass to a diseased popliteal artery
rather than an infrageniculate target?
The authors further considered women who were on
HRT. There were only 34 patients in the entire series tak-
ing hormone replacement therapy by history, and these
women were significantly older and had a much higher
incidence of tobacco abuse. Multiple studies have shown a
negative effect of continued tobacco smoking on bypass
patency. Although the authors performed both univariate
and multivariate analysis, I am concerned that their sample
size is too small to distinguish the confounding variables
of older age and continued smoking on the adverse out-
comes shown in the patients receiving HRT. In addition,
the authors lump together patients receiving estrogen
replacement therapy with those receiving estrogen and
progestin replacement. The risks associated with these
therapies clearly differ. When these subgroups were fur-
ther subdivided, there were just 25 patients receiving ERT
and nine receiving HRT. If you look at the life table the
authors provided for primary graft patency in the hor-
mone replacement therapy group, one notes that only 13
patients had 2-year follow-up. This number is clearly too
low to accurately assess life table patency.
In conclusion, the authors’ premise that women receiv-
ing hormone replacement therapy have worse outcomes
than women not receiving HRT is interesting, and one
could speculate on why such an effect might be present.
However, the data are, at best, inconclusive. Major issues
are the very small numbers of patients receiving HRT and
the lack of specific information on patient compliance,
dosage, and type and duration of HRT. In addition, the
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follow-up is so short that meaningful life table patency esti-
mates probably cannot be made. This study points out the
difficulty in trying to perform subgroup analysis on small
samples. It is possible that the conclusion that HRT
adversely impacts graft patency represents a type I or α
error, that is, a false-positive result. It has been demon-
strated that as trial size decreases the ratio of false-positive
conclusions to true-positive conclusions actually goes up.
Because the authors’ conclusions are based on only 34
women receiving HRT with limited follow-up, the differ-
ence may not be real. The issue of hormone replacement
therapy and its effects on peripheral bypass are important,
but I do not believe the authors have answered the ques-
tion with the present study. A larger number of patients
with longer follow-up are needed to construct reliable life
table assessments to resolve this issue.
I have the following questions for the authors. Could
they explain the low utilization rate of vein? Although 80%
of cases were done for limb salvage, over half the grafts
were PTFE, and arm vein was only used once.
Second, could the authors comment on the frequency
of above-knee popliteal anastomosis?
Third, would the authors comment on the reliability
of patency curves when they are based on such a small
sample size with only 13 patients out to 2 years and 12 at
30 months, by which time the standard of error of the
patency curve was greater than 10%?
Fourth, because of the small sample size, can the
authors be sure that confounding variables such as the
presence of a PTFE graft, as well as the risk factors of
smoking and age, were not the influences of adverse out-
come?
Fifth, why were there no tibial grafts in this group? Did
the authors look at that, and were the data not significant? 
I suspect that hormone replacement therapy is with us
to stay. Women live longer than men do, and the popula-
tion is aging. There is an impressive body of data on estro-
gen and hormone replacement therapy for primary pre-
vention of osteoporosis and menopausal symptoms. In
addition, there is evidence that although there is an initial
increase in thromboembolic events in women on hormone
replacement therapy in the first year after initiation of use,
the subsequent risk of MI and atherosclerosis disease pro-
gression may be reduced during long-term follow-up.
What the authors point out may be true; that is, the pro-
coagulant effects of hormone replacement therapy may
adversely affect the outcome of such patients undergoing
fem-pop bypass. Nonetheless, without a larger sample size
and much longer follow-up, we will not know for sure.
I would like to thank the society very much for the
pleasure of discussing this paper and the authors for bring-
ing us this interesting and provocative issue. Welcome to
Tucson.
Thank you.
Dr Scott Stevens. Thank you, Dr Mills. Certainly at the
cerebral, coronary, and lower extremity locations, revascu-
larization efforts in women fair poorly when compared to
male cohorts. These vascular reconstructions in women are
characterized by decreased patency and survival rates. Many
of us have speculated that the etiology for these vascular fail-
ures is, first, small vessel size and, second, the loss of the
protective antiatherogenic effects of female hormones in
postmenopausal women. With this in mind, we were sur-
prised with results from the HERS (Heart and
Estrogen/progestin Replacement Study) research group
published in JAMA in 1998. This study showed increased
early coronary thromboembolic events in women with pre-
viously established vascular disease receiving hormone
replacement therapy. This is the first and only multicenter
randomized prospective trial. 
To analyze this effect further in a uniform fashion, we
addressed revascularization of the femoropopliteal loca-
tion. We demonstrated a significant decrease in patency
for women receiving hormone replacement therapy. 
Dr Mills, the patients presented in this study represent
a small subset of our patients who receive revascularization
for limb salvage. By far and away, most of our patients who
are operated on for limb salvage receive tibial bypasses or
inframalleolar reconstructions, utilizing vein conduits. We
have a preference for vein whenever it is available.
I agree with Dr Mills that a life table analysis would
not be appropriate to statistically address a patient popula-
tion with numbers this small. Accordingly, we abided by
the recommendations made by the SVS/ISCVS reporting
standards for lower extremity revascularization and used a
Kaplan-Meier curve. This demonstrated our results to be
statistically significant. We did substratify to identify any
difference between estrogen and combined estrogen and
progesterone replacement and established that decreased
patencies were noted in both categories.
Dr Robert Feldtman (Houston, Tex). I would like to
first of all say that taking hormone replacement therapy
away from women should probably qualify surgeons for
hazardous duty pay because these ladies really do need
some help, but I would like to focus more on the definition
of an estrogen replacement. A lot of my patients are taking
phytoestrogens such as dong quai, black cohosh, cat’s claw,
and a lot of other alternative medicine phytoestrogens,
which give all of the same protective effects of pregnant
mare urine, which is Premarin, and I wonder if you actual-
ly looked in your estrogen replacement at the type of estro-
gen the patient was taking, whether it was animal derived
or plant derived.
Dr Stevens. That is an important comment, and, cer-
tainly, studying hormone replacement therapy often bor-
ders on witchcraft. In east Tennessee the desire for hor-
mone replacement therapy is rather straightforward. We
did not substratify the patients but rather looked at all
patients receiving hormone replacement therapy.
Dr Christopher Kwolek (Lexington, Ky). Again, I
would like to congratulate the presenter and the authors
on bringing up a very interesting topic. This question is a
follow-up to the previous one. There is actually a whole
new class of “designer” estrogens that is now being pro-
moted, not only for the cardioprotective effects but also
for osteoporosis protection (ie, raloxifene or Evista), and I
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would argue that this is probably going to be even more
prevalent in our patient population. In having spoken with
the authors about this paper previously, I do not believe
they were able to break out the specific type of estrogen,
but it may be very important for future studies not only to
look at raloxifene or Evista but also to consider other
estrogen-like substances such as tamoxifen. 
My one question would be, when you look at your
overall data, clearly, there was a very high incidence of
smokers in that estrogen replacement group. Realizing
that the numbers are probably very small, were you able to
break out the estrogen replacement smokers versus non-
smokers, and did you see a difference between those two
patient populations?
Dr Stevens. Thanks, Chris. We did correct for smoking
and increased age in the patients receiving hormone
replacement therapy, and we did not break out those
patients receiving designer estrogens. The study was not
designed to address whether or not hormone replacement
therapy should be given or withdrawn, but we do think
that this study addresses an important clinical problem,
one that we face as vascular surgeons. This subset tradi-
tionally gives us challenges with high failure rates. We
found similar phenomena at the tibial and the iliac loca-
tions. We think that the clinical implications may imply
tightening the indications for revascularization in women,
increasing intensity of graft surveillance in these patients,
and liberalizing anticoagulation. 
